177 related articles for article (PubMed ID: 38280047)
1. The EANM Focus 5 consensus on 'molecular imaging and theranostics in prostate cancer': the future begins today.
Oprea-Lager DE; MacLennan S; Dierckx R; Fanti S
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1462-1463. PubMed ID: 38280047
[No Abstract] [Full Text] [Related]
2. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S
Eur Urol; 2024 Jan; 85(1):49-60. PubMed ID: 37743194
[TBL] [Abstract][Full Text] [Related]
3. EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshell.
Kunikowska J; Ambrosini V; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1276-1277. PubMed ID: 33624150
[No Abstract] [Full Text] [Related]
4. Highlights lecture EANM 2016: "Embracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine".
Aboagye EO; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1559-1574. PubMed ID: 28597119
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics.
Zhu Y; Sun Y; Duan Y; Chen Y
Nanomedicine (Lond); 2021 Oct; 16(23):2029-2032. PubMed ID: 34519535
[No Abstract] [Full Text] [Related]
6. Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
Herrmann K; Giovanella L; Santos A; Gear J; Ozgen Kiratli P; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
J Nucl Med; 2022 Dec; 63(12):1836-1843. PubMed ID: 35450957
[TBL] [Abstract][Full Text] [Related]
7. Reawakening of Nuclear Medicine through Molecular Imaging: Quantitative Theranostics and PSMA PET.
Civelek AC
Radiology; 2023 May; 307(4):e230627. PubMed ID: 37070999
[No Abstract] [Full Text] [Related]
8. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.
Czernin J; Calais J
J Nucl Med Technol; 2020 Jun; 48(Suppl 1):82S-83S. PubMed ID: 32605963
[No Abstract] [Full Text] [Related]
9. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of nuclear medicine in haematological tumours-EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours.
Nanni C; Kobe C; Herrmann K; Kunikowska J
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2925-2926. PubMed ID: 37358621
[No Abstract] [Full Text] [Related]
11. Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology.
Jadvar H
J Nucl Med; 2018 Sep; 59(9):1338-1339. PubMed ID: 30030344
[No Abstract] [Full Text] [Related]
12. Alpha emitting nuclides in nuclear medicine theranostics.
Miederer M
Nuklearmedizin; 2022 Jun; 61(3):273-279. PubMed ID: 34624903
[TBL] [Abstract][Full Text] [Related]
13. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [
Lopci E; Hicks RJ; Dimitrakopoulou-Strauss A; Dercle L; Iravani A; Seban RD; Sachpekidis C; Humbert O; Gheysens O; Glaudemans AWJM; Weber W; Wahl RL; Scott AM; Pandit-Taskar N; Aide N
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2323-2341. PubMed ID: 35376991
[TBL] [Abstract][Full Text] [Related]
14. Consensus on molecular imaging and theranostics in prostate cancer.
Fanti S; Minozzi S; Antoch G; Banks I; Briganti A; Carrio I; Chiti A; Clarke N; Eiber M; De Bono J; Fizazi K; Gillessen S; Gledhill S; Haberkorn U; Herrmann K; Hicks RJ; Lecouvet F; Montironi R; Ost P; O'Sullivan JM; Padhani AR; Schalken JA; Scher HI; Tombal B; van Moorselaar RJA; Van Poppel H; Vargas HA; Walz J; Weber WA; Wester HJ; Oyen WJG
Lancet Oncol; 2018 Dec; 19(12):e696-e708. PubMed ID: 30507436
[TBL] [Abstract][Full Text] [Related]
15. EANM Focus 1: one small step for two men, one giant leap for a specialty.
Fanti S; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1400-1401. PubMed ID: 31016331
[No Abstract] [Full Text] [Related]
16. Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles.
Kilcoyne A; Harisinghani MG; Mahmood U
J Nucl Med; 2016 Oct; 57(Suppl 3):105S-110S. PubMed ID: 27694162
[TBL] [Abstract][Full Text] [Related]
18. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.
Herrmann K; Giovanella L; Santos A; Gear J; Kiratli PO; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2300-2309. PubMed ID: 35403861
[TBL] [Abstract][Full Text] [Related]
19. PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers.
An S; Huang G; Liu J; Wei W
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):3973-3976. PubMed ID: 35916921
[No Abstract] [Full Text] [Related]
20. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1626-1638. PubMed ID: 33604691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
